Reduced glutamate decarboxylase 1 underlies morphine-promoted lung metastasis of triple-negative breast cancer in mice
S. H. Chen, C.-H. Shih, T.-L. Ke, C.-N. Hsiung, K.-C. Chen, Z.-X. Huang, T.-H. Chuang, L.-K. Chen, L. Chen
Abstract
IntroductionMorphine is commonly used for cancer-related pain management. Long-term morphine use is not only addictive but also has been associated with risk factor for cancer. MethodsWe intraperitoneally administered morphine to mice for 14 days and then implanted EO771 cells, triple negative breast cancer cells, into their mammary fat pad. After primary tumors were removed on 38th day, a subset of mice were continuously giving saline or morphine until the 68th day. Tumor size, organ metastasis, and tumor RNA expression were analyzed. ResultsOur results revealed that long-term morphine treatment increased lung metastasis in the triple-negative breast cancer mouse model. To determine cellular pathways responsible for morphine-mediated metastasis, we performed RNA sequencing analysis to compare transcriptional profiles during metastasis. Transcriptional analysis revealed a significant number of genes down-regulated by morphine treatment. Based on pathway analysis, we focused on the novel effect of morphine on down-regulating taurine/hypotaurine biosynthesis. Considering that morphine, droperidol (dopamine receptor antagonist), and naloxone (opioid receptor antagonist) may act through opioid receptor or dopamine receptor, we further demonstrated that taurine reduced EO771 cell invasion caused by morphine, but not by droperidol, or naloxone treatment. In addition, morphine treatment significantly reduced the expression of GAD1, one of the enzymes required for biosynthesis of taurine, whereas droperidol and naloxone did not. ConclusionThese novel findings of morphine reduces GAD1 level and taurine reverses invasion suggest that taurine could potentially be employed as a supplement for triple negative breast cancer patients using morphine as pain management. Key MessagesO_LIMorphine usage has been implicated in modulating immune system and affecting cancer progression. C_LIO_LILong-term usage of morphine promotes metastasis of triple negative breast cancer through reducing taurine biosynthesis. C_LIO_LIThese novel findings of morphine reduces GAD1 level and taurine reverses invasion suggest that taurine could potentially be employed as a supplement for triple negative breast cancer patients using morphine as pain management. C_LI
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Opioids trigger breast cancer metastasis through E-Cadherin downregulation and STAT3 activation promoting epithelial mesenchymal transition
Sabrina Tripolt, Vanessa M. Knab, … Daniela A. Fux·bioRxiv·Oct 15, 2018
- The metronomic combination of paclitaxel with cholinergic agonists inhibits triple negative breast tumor progression. Participation of M2 receptor subtype
A. Espanol, A. Salem, … M. E. Sales·bioRxiv·Nov 29, 2019
- Morphine analgesia and mu opioid receptor signaling require programed death protein 1 (PD-1)
Zilong Wang, Changyu Jiang, … Ru‐Rong Ji·bioRxiv·Mar 17, 2019
- Inhibition of the polyamine synthesis enzyme ornithine decarboxylase sensitizes triple-negative breast cancer cells to cytotoxic chemotherapy
R. C. Geck, J. R. Foley, … A. Toker·bioRxiv·Jan 8, 2020
- Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition
P. V. Raninga, A. Lee, … K. K. Khanna·bioRxiv·Oct 11, 2019
- GABA-GABA_A Receptor Signaling Orchestrates Invasion and Metastasis in Triple Negative Breast Cancer
Esther Afolayan, Boxon Zhang, … Karla C. Williams·bioRxiv·Oct 3, 2025